CION Ameerpet
Childhood Cancer Types — Parent’s Guide
Hepatoblastoma — liver cancer in children, explained
Medically reviewed by Dr. C. Raghavendra Reddy, DM (Medical Oncology, Gold Medal) · Last reviewed June 2026
If your young child has been found to have a liver tumour — or if you have heard the word “hepatoblastoma” for the first time — you deserve a clear, unhurried explanation before anything else happens. Hepatoblastoma is the most common primary liver cancer in young children. It usually affects children under five years of age, and when identified and managed at a specialist centre, the outlook for many children is meaningful. This page explains what hepatoblastoma is, how it is recognised, and what the path from diagnosis to treatment typically looks like — in language you can share with family.
- Tumour board for every child — a full multidisciplinary team (oncologist, surgeon, radiologist, pathologist) reviews each case before treatment begins
- 45-minute consultations — your questions are heard fully; no rushed decisions on your child’s care plan
- Free first consultation — paediatric oncology assessment at no charge for first-time patients
- Transparent costs — written treatment plan and cost breakdown before anything begins; decisions for healing, not billing
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Understanding liver cancer in children
Hepatoblastoma types and features — what every parent should know
Hepatoblastoma is not a single, uniform disease. Understanding the different tumour types, where the tumour is in the liver, and what the AFP blood test means helps parents make sense of the reports and conversations they will encounter on their child’s journey.
Favourable biology
Pure Fetal (Well-Differentiated) Hepatoblastoma
This subtype is made up of cells that closely resemble normal fetal liver cells. They are well-differentiated, meaning they look relatively mature under the microscope. Pure fetal hepatoblastoma is associated with a more predictable response to treatment. When the pathology report from surgery describes “pure fetal histology,” it is clinically meaningful: treatment teams may consider a less intensive approach after complete surgical removal in selected cases. This is always decided within the full context of staging and AFP response, not histology alone.
- Cells resemble normal fetal liver tissue
- Generally considered the most favourable histological subtype
- Complete surgical removal is a key goal
Most common presentation
Embryonal and Mixed Hepatoblastoma
The majority of hepatoblastomas are composed of a mixture of cell types — embryonal cells, fetal cells, and sometimes primitive stromal or mesenchymal components. Embryonal cells are more primitive and less differentiated than fetal cells. Mixed hepatoblastoma is the most frequently encountered subtype in clinical practice. Treatment protocols address these tumours with a standard approach involving chemotherapy and surgery. The exact composition of the tumour is determined after the specimen is examined by a pathologist following surgery or biopsy.
- Mixture of embryonal and fetal cell patterns
- Accounts for the majority of hepatoblastoma diagnoses
- Responds to established chemotherapy-surgery protocols
Needs close attention
Small Cell Undifferentiated (SCU) Subtype
A small proportion of hepatoblastomas contain areas of small, undifferentiated cells — sometimes described as “small cell undifferentiated” or SCU. These cells are very primitive, with little resemblance to normal liver tissue. SCU hepatoblastoma is associated with a more aggressive behaviour and a lower AFP level in some cases, which makes monitoring more reliant on imaging than on AFP alone. Specialist pathological review is especially important when SCU features are identified, as they influence the treatment plan. This subtype highlights why accurate pathology at a centre with paediatric oncology expertise matters.
- Rare subtype with primitive, undifferentiated cell features
- AFP may be lower than in other subtypes
- Requires specialist pathology review and adapted treatment
Key diagnostic marker
Alpha-Fetoprotein (AFP) — The Liver Cancer Marker
Alpha-fetoprotein (AFP) is a protein produced naturally by the developing fetal liver. After birth, AFP levels normally fall rapidly to low adult levels. In most children with hepatoblastoma, AFP is produced by the tumour in very large quantities, making blood AFP measurement one of the most useful tools available in this cancer. It supports diagnosis, shows how well the tumour is responding to chemotherapy (AFP should fall as the tumour shrinks), guides the timing and decision around surgery, and serves as an early recurrence signal in follow-up. A rising AFP after treatment ends always prompts imaging re-assessment, even before any lump is detectable.
- Elevated in the great majority of hepatoblastoma cases
- Falls with effective chemotherapy — a direct treatment monitor
- Checked regularly throughout treatment and follow-up
Hepatoblastoma is one of several childhood liver conditions covered in our paediatric cancer programme. For a broader overview of all childhood cancers, visit the Pediatric Cancer hub. If your child’s doctor mentioned an abdominal lump or swelling, see also our guide to abdominal swelling and lumps in young children.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your child deserves a full second opinion before treatment begins
Every case of hepatoblastoma is different. A 45-minute review with our paediatric oncology team — looking at imaging, AFP, and pathology together — can meaningfully shape the plan.
The clinical journey
How hepatoblastoma is diagnosed and treated — step by step
When a liver tumour is found in a young child, a clear, coordinated sequence of steps follows. Understanding this journey in advance reduces the anxiety of the unknown and helps you ask the right questions at each appointment.
Ultrasound of the abdomen — the first look
When a parent or doctor notices an abdominal swelling in a young child, the first investigation is almost always an abdominal ultrasound. This is a quick, painless scan that does not use radiation. It can confirm whether there is a mass in the liver, give a rough sense of its size, and show whether the mass appears solid (more concerning) or fluid-filled (usually benign). If the ultrasound shows a solid liver mass in a young child, the next step is arranged promptly. An ultrasound finding of a liver mass does not on its own confirm cancer — further imaging is always done before any conclusions are drawn.
AFP blood test — the tumour marker that guides everything
A blood test to measure alpha-fetoprotein (AFP) is one of the most important early steps in the evaluation of a suspected liver mass in a young child. In most children with hepatoblastoma, AFP is markedly elevated — often in the thousands or tens of thousands above the upper limit of normal. A high AFP in a young child with a liver mass on imaging is a strong pointer towards hepatoblastoma, and it begins the team’s clinical reasoning before a biopsy is even considered. AFP is measured repeatedly during chemotherapy, at surgery, and throughout follow-up, because each value carries information about how the tumour is behaving.
CT scan or MRI — mapping the tumour in detail
After the initial ultrasound and AFP result, the team arranges a detailed cross-sectional scan — usually a CT scan of the abdomen and chest, or an MRI. This gives far more detailed information than ultrasound: the exact size and location of the tumour within the liver, which of the liver’s four sections it involves, whether it is pressing on or involving major blood vessels (a factor that determines surgical risk), and whether there are any deposits in the lungs (the most common site of spread for hepatoblastoma). The results of this scan determine the PRETEXT staging, which is the framework the team uses to plan chemotherapy and decide the timing and approach of surgery.
Multidisciplinary tumour board review — the plan is made together
At CION, every child’s case is presented at a multidisciplinary tumour board meeting before any treatment decision is made. This meeting brings together the paediatric oncologist, surgical oncologist, radiologist, and pathologist, as well as other specialists as needed. Together, they review all the imaging, the AFP result, the child’s age and general health, and any relevant family history. The board reaches a consensus on whether to start with chemotherapy (the approach for most cases), whether surgery is feasible upfront, and what monitoring plan is needed. You will receive a clear written explanation of the plan that the team has agreed upon. We do not make rushed decisions.
Chemotherapy — shrinking the tumour before surgery
For most children with hepatoblastoma, chemotherapy is given before surgery. This approach is used because it shrinks the tumour, reduces the risk of complications during surgery, and allows the surgical team to plan a more precise and complete removal. Chemotherapy is given in cycles, with rest periods in between. During each cycle, blood counts and AFP are checked regularly. The team uses AFP response as one of the key indicators of how well the tumour is responding. If AFP is falling consistently, the chemotherapy is working. The number of chemotherapy cycles before surgery depends on how the tumour responds and what the staging was at diagnosis.
Surgery — removing the tumour from the liver
Once the tumour has responded to chemotherapy and the team judges it is safe and achievable, surgery is performed to remove the tumour. The goal is complete removal with clear margins — meaning no tumour cells at the edges of what was removed. The type of surgery depends on where in the liver the tumour is located. Some children require removal of a segment or lobe of the liver; others need more extensive resection. For a small number of children where the tumour is too extensive even after chemotherapy, or where it involves both lobes of the liver beyond what standard resection can address, liver transplantation is considered. The liver has a remarkable ability to regenerate after partial resection, and children generally recover liver function well.
Post-surgery chemotherapy and long-term follow-up
After surgery, most children receive additional cycles of chemotherapy to reduce the risk of the tumour returning. Once all treatment is complete, regular follow-up begins. This includes AFP blood tests and imaging at planned intervals. The follow-up schedule is more frequent in the first two years after treatment, and gradually becomes less frequent over time as the risk of recurrence falls. Long-term follow-up also looks at general health, growth, liver function, and any potential late effects of treatment. Your child’s team will give you a clear schedule and explain what each appointment is checking.
For information about liver cancer in adults, see our Liver Cancer overview page. For a full picture of all paediatric cancers we manage, visit the Pediatric Cancer hub.
Walk this journey with us
You should not have to face this alone
We walk every step of this journey with you — from the moment you first sit down with us to the day your child finishes treatment and beyond. Every decision is made together, at your pace.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Your questions about hepatoblastoma — answered
What is hepatoblastoma and why does it develop in children?
Hepatoblastoma is a cancerous tumour that arises in the liver. It is the most common primary liver cancer in young children, and it occurs most often in children under the age of five years, with the peak incidence between one and two years of age. The tumour develops from immature liver cells — primitive cells that were part of the fetal liver and did not fully mature as the child grew. In most cases, no single clear cause is identified, but hepatoblastoma is known to be more common in children who were born prematurely (particularly at very low birth weight) and in children with certain rare genetic conditions such as Beckwith-Wiedemann syndrome or familial adenomatous polyposis. When a child develops hepatoblastoma without any of these known risk factors, it is described as sporadic — meaning it arose without a clear inherited or environmental reason.
What are the early signs and symptoms of hepatoblastoma?
In its early stages, hepatoblastoma often does not cause pain, and the first sign that parents notice is usually a swelling or lump in the child’s abdomen — sometimes visible as a visible bump under the right ribcage, and sometimes felt during bathing or dressing. Because the tumour can grow to a large size before it causes noticeable discomfort, it is sometimes already substantial by the time it is first discovered. Other signs that may accompany the lump include: loss of appetite and unexplained weight loss; increasing abdominal girth (the belly becoming visibly larger); unusual tiredness or lack of energy; nausea or vomiting, particularly after eating; and, in some children, jaundice (yellowing of the skin or whites of the eyes) if the tumour is pressing on bile ducts. Fever is not a typical feature of hepatoblastoma. If you notice any unexplained abdominal swelling in a young child, please see a doctor promptly for an examination — an abdominal mass in a child always needs medical assessment without delay.
How is hepatoblastoma diagnosed?
When a doctor suspects a liver mass in a child, the diagnostic pathway begins with imaging and blood tests. An ultrasound of the abdomen is usually the first step — it can confirm that a mass is present in the liver, show its size and location, and give initial information about whether the mass looks solid or fluid-filled. This is followed by a CT scan or MRI of the abdomen to map the tumour in detail: its exact extent within the liver, whether it involves major blood vessels, and whether there is spread to nearby lymph nodes or the lungs. A blood test to measure alpha-fetoprotein (AFP) is a key part of diagnosis — AFP is a protein normally produced in high amounts by the fetal liver, and it is markedly elevated in the great majority of children with hepatoblastoma. The AFP level also serves as a useful marker for monitoring response to treatment. Depending on the clinical picture, a tissue biopsy may or may not be done before treatment begins; the decision depends on imaging certainty and the treatment protocol the team is following.
What does staging mean for hepatoblastoma?
Hepatoblastoma staging describes how the tumour is distributed in the liver and whether it has spread to other parts of the body. Most specialist centres today use a system called PRETEXT (PRE-Treatment EXTent of disease), which divides the liver into four sections and describes how many of those sections contain tumour, whether major blood vessels are involved, and whether the tumour has spread beyond the liver. PRETEXT I means the tumour is in one section of the liver and three sections are free of disease. PRETEXT II and III describe progressively more extensive liver involvement. PRETEXT IV means all four liver sections contain tumour. In addition to the PRETEXT classification, the team notes whether there is spread to the lungs, lymph nodes, or other organs. This full staging picture — including AFP level — shapes whether chemotherapy is given first (to shrink the tumour before surgery) or whether surgery is considered upfront, and how intensive treatment needs to be.
What does treatment for hepatoblastoma involve?
Treatment for hepatoblastoma typically involves a combination of chemotherapy and surgery, and the sequence depends on the extent of disease at diagnosis. For most children, chemotherapy is given first — before surgery — to shrink the tumour and make it more likely that surgery can remove it completely. The goal of surgery is to remove all tumour tissue with clear margins. In a smaller number of children where the tumour is very localised at diagnosis, surgery may be performed first without prior chemotherapy. For tumours that are too extensive to be removed safely even after chemotherapy, or in rare cases where the tumour involves both lobes of the liver extensively, liver transplantation may be considered. After surgery, additional chemotherapy cycles are given in most cases to address any remaining microscopic disease. At CION, every child’s case is reviewed at a multidisciplinary tumour board — paediatric oncologist, surgical oncologist, radiologist, and pathologist together — before any treatment decision is made. We do not make rushed decisions.
What does a persistently high AFP level in my child mean, and why does the team monitor it?
Alpha-fetoprotein (AFP) is a protein that hepatoblastoma tumours typically produce in large amounts. At the time of diagnosis, the AFP level in most children with hepatoblastoma is markedly above normal. Oncologists use AFP as a tumour marker — meaning that as treatment progresses, the AFP level should fall as the tumour shrinks. If AFP drops appropriately with chemotherapy, it is a sign that the treatment is working. If AFP does not fall as expected, or rises again after initially falling, it prompts the team to reassess — repeating imaging to look for resistant disease or early signs of recurrence. After treatment ends, AFP is checked at regular intervals during follow-up for the same reason: a rising AFP level can be an early signal that the tumour is returning, even before it is large enough to be seen on imaging. For a small number of children, AFP levels may not be markedly elevated at diagnosis — these cases require clinical and imaging-based assessment rather than AFP-guided monitoring.
Pediatric Cancer A–Z
Explore All Pediatric Cancer Topics
Browse our complete library of parent-facing guides, grouped by topic — from warning signs and cancer types to diagnosis, treatment, side-effect care, survivorship and family support.